| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2012-08-448977 |
| P698 | PubMed publication ID | 23435462 |
| P50 | author | Emily Blyth | Q45359139 |
| Peter J Shaw | Q56938925 | ||
| David J Gottlieb | Q57023130 | ||
| Kenneth Micklethwaite | Q58808458 | ||
| P2093 | author name string | Karen Byth | |
| Jane Burgess | |||
| Chun K K Ma | |||
| Leighton Clancy | |||
| Shivashni Deo | |||
| Renee Simms | |||
| Ming-Celine Dubosq | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 3745-3758 | |
| P577 | publication date | 2013-02-22 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation | |
| P478 | volume | 121 |
| Q93085644 | "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients |
| Q38288125 | Accelerating immune reconstitution after hematopoietic stem cell transplantation |
| Q34273968 | Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. |
| Q61817999 | Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation |
| Q40895824 | Adoptive T cell therapy for the treatment of viral infections |
| Q26781064 | Adoptive T-cell therapy for fungal infections in haematology patients |
| Q38172451 | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors |
| Q39044990 | Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. |
| Q38291751 | Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors |
| Q29393780 | Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes |
| Q54213856 | Antiviral T-Cells for Adenovirus in the Pre-Transplant Period: a Bridge Therapy for Severe Combined Immunodeficiency. |
| Q27028006 | Antiviral T-cell therapy |
| Q36962638 | Antiviral cell therapy: is this the future? |
| Q40944156 | Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System |
| Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
| Q28073770 | CMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive Therapies |
| Q42181212 | CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers |
| Q38942459 | CMV-specific immune reconstitution following allogeneic stem cell transplantation |
| Q34468247 | Calnexin induces expansion of antigen-specific CD4(+) T cells that confer immunity to fungal ascomycetes via conserved epitopes. |
| Q98735538 | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| Q92341814 | Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host |
| Q33820695 | Controlling cytomegalovirus: helping the immune system take the lead |
| Q52564628 | Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. |
| Q55322590 | DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. |
| Q88426253 | Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD |
| Q37426542 | Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation |
| Q36920445 | Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis |
| Q26799602 | Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients |
| Q37504023 | Evaluation of T Cell Immunity against Human Cytomegalovirus: Impact on Patient Management and Risk Assessment of Vertical Transmission |
| Q100992475 | Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection |
| Q55380614 | Genetically enhanced T lymphocytes and the intensive care unit. |
| Q54204795 | Helper T-Cell Responses and Pulmonary Fungal Infections. |
| Q28069489 | How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients |
| Q26850340 | Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm |
| Q92700078 | Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients |
| Q40466464 | Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. |
| Q36956443 | Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation |
| Q39382670 | Immunotherapy for transplantation-associated viral infections |
| Q35958223 | Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia |
| Q33941012 | Immunotherapy: opportunities, risks and future perspectives |
| Q39865680 | Impact of early CMV reactivation in cord blood stem cell recipients in the current era. |
| Q33597783 | Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation |
| Q38194133 | Improving engraftment and immune reconstitution in umbilical cord blood transplantation |
| Q90567346 | Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota |
| Q54214517 | Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. |
| Q45324037 | Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases |
| Q64377135 | Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells |
| Q97537238 | Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells |
| Q36384572 | Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. |
| Q91013920 | Modulation of innate and adaptive immunity by cytomegaloviruses |
| Q64102170 | Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
| Q89366245 | New Developments in the Management of Cytomegalovirus Infection After Transplantation |
| Q40092234 | Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation |
| Q36814589 | Pharmacotherapy versus T lymphocytes for CMV. |
| Q26801365 | Preventing stem cell transplantation-associated viral infections using T-cell therapy |
| Q98156927 | Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity |
| Q28079823 | Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications |
| Q35226610 | SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation |
| Q61798868 | Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation |
| Q37058107 | T cells for viral infections after allogeneic hematopoietic stem cell transplant |
| Q33734872 | The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. |
| Q35477534 | The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation |
| Q38547042 | The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients |
| Q37592177 | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care |
| Q40370932 | Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. |
| Q37721514 | Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells |
| Q47603836 | Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. |
| Q64375296 | Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders |
| Q38797555 | Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections |
| Q37632938 | γδ T Cell-Mediated Immunity to Cytomegalovirus Infection. |
Search more.